Regencell Bioscience Holdings Limited Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price

Regencell Bioscience Holdings Limited (RGC) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $0.40 per share as of 2025-06-30, per its 20-F filed 2025-10-31.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2025-10-31

2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $0.40.
2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $0.15; Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed $5.83.
2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $5.81.
2023-06-29: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $0.15.

Period end	Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price	Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed
2025-06-30	$0.40 20-F · filed 2025-10-31
2024-06-30	$0.15 20-F · filed 2025-10-31	$5.83 20-F · filed 2024-10-25
2023-06-30	$5.81 20-F · filed 2024-10-25
2023-06-29	$0.15 20-F · filed 2025-10-31
2022-06-30	$5.45 20-F · filed 2024-10-25
2021-06-30	$5.45 20-F · filed 2023-10-27